Mayank Mamtani

Liang Cheng

Cheng Li

Elaine Kim

Unknown Analyst

- Vaxart, Inc. received a decision letter from the Nasdaq Hearings Panel on **August 27, 2025**, granting its request for an extension to regain compliance with the Nasdaq minimum bid price requirement.  **[72444_0001437749-25-028047_ex_858217.htm:0]** 
- The extension is subject to several conditions, including obtaining stockholder approval for a reverse stock split (RSS) by **September 5, 2025**, completing the RSS by **October 6, 2025**, and demonstrating compliance with the Bid Price Rule by **October 17, 2025**.  **[72444_0001437749-25-028047_ex_858217.htm:0]** **[72444_0001437749-25-028047_vxrt20250829_8k.htm:2]** 
- Failure to obtain stockholder approval for the RSS by the September 5, 2025, deadline will result in the delisting of the company's securities.  **[72444_0001437749-25-028047_vxrt20250829_8k.htm:2]**

Vaxart (VXRT)